$22 out-of-pocket costs
for many eligible patients;
restrictions apply

The NAFTIN® (Naftifine HCl) Gel, 2% co‑pay savings program8

Help patients save on prescriptions

  • $22 out-of-pocket costs for many eligible patients; restrictions apply
  • Offer not valid for patients covered by Medicare, Medicaid, or any federal or state pharmaceutical assistance programs
Print Savings Card


This savings card is not valid for use by patients covered by any federal or state funded healthcare program (including, but not limited to, Medicare (Part D and Medigap), Medicaid, any state pharmaceutical assistance program, TRICARE, VA, or DoD), or private indemnity or HMO insurance plans that reimburse patient for the entire cost of prescription drugs. Offer good only in the U.S., including Puerto Rico. Not valid if an AB-rated generic drug is available for the product. Void where prohibited by law, taxed, or restricted. This offer cannot be combined with any other promotional offer. Sebela Pharmaceuticals reserves the right to rescind, revoke, or amend this offer without notice at any time. No cash value. Not eligible for sale, purchase, trade or counterfeit.

ExpandCollapseClick to See Complete Safety InformationClose

NAFTIN® (Naftifine HCl) Gel, 2%


NAFTIN GEL, 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.


In clinical trials with NAFTIN Gel, 2%, the most common adverse reactions (2%) were application site reactions.


If redness or irritation develops with the use of NAFTIN Gel, 2%, treatment should be discontinued.

Please click here for NAFTIN full prescribing information

REFERENCES: 1. Vlahovic TC. Choosing the right vehicle. Podiatry Management. June/July 2008;209-218. 2. Data on file, Sebela Pharmaceuticals Inc. 3. Naftin (naftifine hydrochloride) Gel 2% [package insert]. Roswell, GA; Sebela Pharmaceuticals Inc.; December 2017. 4. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration/Center for Drug Evaluation and Research website. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=204286&Appl_type=N. Accessed November 7, 2017. 5. Plaum S, Verma A, Fleischer AB, Olayinka B, Hardas B. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream or gel 2%. J Drugs Dermatol. 2013;12(9):1004-1008. 6. Stein Gold L, Parish L, Vlahovic T, Kircik L, et al. Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs Dermatol. 2013;12(8):911-918. 7. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8. 8. NAFTIN 2% Co-Pay Savings Offer. Sebela Pharmaceuticals Inc., January 2017. 9. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. November 2011;10(11):1282-1288. 10. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. October 2011;10(10):1142-1147. 11. Robbins CM, Elston DM. Tinea pedis treatment & management. Medscape Web site. http://emedicine.medscape.com/article/1091684-overview. Updated November 19, 2015. Accessed February 22, 2016. 12. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed. Elsevier Inc. Ebook; 2013:460-472.